Sort   by:  
 Page size 
GenomicsCRISPR-Cas9 RBM10 synthetic lethality screen
CRISPR-Cas9 RBM10 synthetic lethality screen
PRJEB60386 | ENA
ProteomicsMetabolic resistance to the inhibition of mitochondrial transcription revealed by CRISPR-Cas9 screen
Cancer cells depend on mitochondria to sustain their increased metabolic needs therefore, mitochondria constitute an interesting target for cancer treatment. We recently developed novel small-molecule inhibitors of mitochondrial transcription (IMTs) that selectively target mitochondrial gene express...
ORGANISM(S): Homo sapiens (Human) 
2021-11-11 | PXD026481 | Pride
Mtdna Cancer Crispr-cas9 genetic screen Inhibitor of mitochondrial transcription Chemoresistance 
GenomicsGenome-wide CRISPR-Cas9 knockout screen in MCF10A with ATP-competitive inhibition of CDC7 (XL-413)
The coordinated activation of DNA replication origins is important for efficient DNA synthesis and genome stability. S-phase cyclin dependent kinases (CDKs) together with CDC7 kinase, are essential to origin activation by converting the pre-replicative complex into a fully active helicase. To identi...
ORGANISM(S): Homo sapiens 
2026-09-30 | E-MTAB-17434 | biostudies-arrayexpress
ProteomicsA CRISPR/Cas9-mediated screen identifies regulators of early plasma cell differentiation
The differentiation of B cells into antibody-secreting cells depends on cell division-coupled, epigenetic and other cellular processes that are incompletely understood. We have developed a CRISPR/Cas9-based screen that models an early stage of T cell-dependent plasma cell differentiation and measure...
ORGANISM(S): Mus musculus (Mouse) 
2022-12-22 | PXD038201 | Pride
Plasmablasts Screen Plasma cell differentiation Crispr/cas9 Regulators Gene knockout Antibody-secreting cells Plasma cells and antibody secretion 
GenomicsIn vivo CRISPR/Cas9 screen to identify candidate therapeutic gene targets to enhance docetaxel efficacy in prostate cancer
Docetaxel chemotherapy in metastatic prostate cancer offers only a modest survival benefit due to emerging resistance. To identify candidate therapeutic gene targets, we applied a murine prostate cancer orthograft model that recapitulates clinical invasive prostate cancer in a genome-wide CRISPR/Cas...
ORGANISM(S): Mus musculus 
2020-10-07 | E-MTAB-9482 | biostudies-arrayexpress
TranscriptomicsGenome-wide CRISPR-Cas9 screen identifies protein-coding genes and microRNAs important in FLT3-ITD+ AML (MV4-11) cellular growth
The functional relevance of many microRNAs in the context of tumor biology remains unclear. Using CRISPR-Cas9 technology, we performed a global loss-of-function screen to test the impact of individual microRNAs on the growth of FLT3-ITD positive leukemia cells. This approach identified both evolutio...
ORGANISM(S): Homo sapiens 
2016-07-01 | E-GEOD-71539 | biostudies-arrayexpress
GenomicsGenome-wide CRISPR-Cas9 screen (TKOv3) data on SUN2 degradation
Genome-wide CRISPR-Cas9 screen (TKOv3) data on SUN2 degradation
PRJEB54102 | ENA
GenomicsCRISPR-Cas9 RBM10 synthetic lethality screen
Genome-wide CRISPR-Cas9 knockout screen using TKOv1 sgRNA library was performed in isogenic RBM10-proficient and RBM10-deficient HCC827 cells.
ORGANISM(S): Homo sapiens 
2023-03-04 | E-MTAB-12724 | biostudies-arrayexpress
TranscriptomicsGenome-wide CRISPR-Cas9 screens reveal loss of redundancy between PKMYT1 and WEE1 in Glioblastoma stem-like cells
To identify new therapeutic targets for Glioblastoma (GBM), we performed genome-wide CRISPR-Cas9 "knockout" (KO) screens in patient-derived GBM stem-like cells (GSCs) and human neural stem/progenitors (NSCs), non-neoplastic stem cell controls, for genes required for their in vitro growth. ...
ORGANISM(S): Homo sapiens 
2016-02-15 | E-GEOD-70038 | biostudies-arrayexpress
GenomicsGenome-wide CRISPR-Cas9 screen to identify SFV4 receptor
Genome-wide CRISPR-Cas9 screen to identify SFV4 receptor
PRJNA1194606 | ENA
Sort   by:  
 Page size